Angiodynamics, Inc. ( (ANGO) ) has released its Q1 earnings. Here is a breakdown of the information Angiodynamics, Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
AngioDynamics, Inc. is a leading medical technology company that focuses on enhancing vascular health, expanding cancer treatment options, and improving patient quality of life through innovative devices and technologies.
In its fiscal year 2026 first-quarter earnings report, AngioDynamics reported significant growth in its Med Tech segment, with a 26.1% increase in net sales, marking the fourth consecutive quarter of over 20% growth. The company also reported an adjusted EBITDA of $2.2 million, a notable improvement from a negative figure in the prior year, and raised its full-year guidance for various financial metrics.
Key financial highlights include a 12.2% increase in net sales to $75.7 million, driven by robust performance in the Med Tech segment. The Auryon peripheral atherectomy platform, thrombus management platform, and NanoKnife system contributed significantly to this growth. The company also achieved a gross margin of 55.3%, reflecting operational efficiencies and increased Med Tech revenue.
AngioDynamics continues to make strides in clinical trials and research, enrolling the first patients in the AMBITION BTK and RECOVER-AV trials and publishing positive results from the NanoKnife PRESERVE study. These efforts underscore the company’s commitment to advancing medical technology and expanding its clinical presence globally.
Looking ahead, AngioDynamics remains optimistic about its financial performance for the rest of fiscal year 2026, with expectations to be cash flow positive and to continue delivering profitable growth through strategic investments and operational excellence.